Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tambiciclib - GenFleet Therapeutics/Sellas Life Sciences

Next Previous
Drug Profile

Tambiciclib - GenFleet Therapeutics/Sellas Life Sciences

Alternative Names: GFH-009; SLS 009 - Sellas Life Science Group; SLS-009 - Sellas Life Sciences Group

Latest Information Update: 09 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GenFleet Therapeutics
  • Developer GenFleet Therapeutics; Sellas Life Sciences Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Diffuse large B cell lymphoma; Haematological malignancies; Peripheral T-cell lymphoma
  • Phase I Solid tumours
  • Preclinical Colorectal cancer

Most Recent Events

  • 09 Sep 2025 Chemical structure information added.
  • 16 Jul 2025 Sellas Life Sciences Group hold phase II meeting with the US FDA for Acute myeloid leukemia (First line therapy, Newly diagnosed), prior to July 2025
  • 16 Jul 2025 Efficacy and adverse events data from a phase II trial in Acute myeloid leukemia released by SELLAS Life Sciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top